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BACKGROUND AND PURPOSE
Amyloid-b (Ab) aggregation into synaptotoxic, prefibrillar oligomers is a major pathogenic event underlying the
neuropathology of Alzheimer’s disease (AD). The pharmacological and neuroprotective properties of a novel Ab aggregation
inhibitor, SEN1269, were investigated on aggregation and cell viability and in test systems relevant to synaptic function and
memory, using both synthetic Ab1-42 and cell-derived Ab oligomers.
EXPERIMENTAL APPROACH
Surface plasmon resonance studies measured binding of SEN1269 to Ab1–42. Thioflavin-T fluorescence and MTT assays were
used to measure its ability to block Ab1–42–induced aggregation and reduction in cell viability. In vitro and in vivo long-term
potentiation (LTP) experiments measured the effect of SEN1269 on deficits induced by synthetic Ab1–42 and cell-derived Ab
oligomers. Following i.c.v. administration of the latter, a complex (alternating-lever cyclic ratio) schedule of operant
responding measured effects on memory in freely moving rats.
KEY RESULTS
SEN1269 demonstrated direct binding to monomeric Ab1–42, produced a concentration-related blockade of Ab1–42 aggregation
and protected neuronal cell lines exposed to Ab1–42. In vitro, SEN1269 alleviated deficits in hippocampal LTP induced by Ab1–42
and cell-derived Ab oligomers. In vivo, SEN1269 reduced the deficits in LTP and memory induced by i.c.v. administration of
cell-derived Ab oligomers.
CONCLUSIONS AND IMPLICATIONS
SEN1269 protected cells exposed to Ab1–42, displayed central activity with respect to reducing Ab-induced neurotoxicity and
was neuroprotective in electrophysiological and behavioural models of memory relevant to Ab-induced neurodegeneration. It
represents a promising lead for designing inhibitors of Ab-mediated synaptic toxicity as potential neuroprotective agents for
treating AD.
Abbreviations
ALCR, alternating-lever cyclic-ratio; AD, Alzheimer’s disease; APP, amyloid precursor protein; Ab, amyloid-b; CM,
conditioned medium; DMSO, dimethyl sulfoxide; fEPSP, extracellular field excitatory post-synaptic potential; HFS,
high-frequency stimulation; LTP, long-term potentiation; MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium;
SA, streptavidin
Introduction
Progressive accumulation of amyloid-b (Ab) assemblies is con-
sidered fundamental to the development of neurodegenera-
tive pathology and inflammation that contribute to
Alzheimer’s disease (AD) (Tanzi et al., 2004). The key patho-
genic event in the onset of AD appears to be the formation of
extracellular soluble Ab peptide into synaptotoxic, prefibrillar
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oligomers (Verdile et al., 2004; Walsh and Selkoe, 2004a,b),
and accumulating evidence supports a cogent argument that
compounds preventing the generation of toxic Ab assemblies
could provide successful new treatments for AD (Estrada and
Soto, 2007). Several studies indicate that AD severity corre-
lates closely with accumulation of soluble oligomers of Ab
(Lue et al., 1999; McLean et al., 1999; Wang et al., 1999).
Consequently, pharmacotherapies that block initial Ab
assembly prior to the stage of oligomerization (Selkoe and
Schenk, 2003; Walsh and Selkoe, 2004b), so as to prevent
oligomerization and allow natural neurophysiological clear-
ance mechanisms to effect the removal of Ab (Golde, 2006;
Walsh and Selkoe, 2007) and preserve normal synaptic func-
tion, might provide an effective treatment strategy.
AD is considered a product of initial synaptic failure that
precedes neuronal degeneration, and Ab-induced dysfunc-
tion of synaptic plasticity appears to contribute to early
memory loss (Haass and Selkoe, 2007; Shankar et al., 2008).
Long-term potentiation (LTP), a well-established model of
synaptic plasticity related to memory, involves a sustained
increase in excitatory synaptic transmission; and inhibition
of LTP by Ab may mimic an early manifestation of the
memory loss seen in AD (Ondrejcak et al., 2010). Cultured
cells that express human Ab precursor protein (APP) generate
and secrete soluble oligomers of human Ab, which contain
the Ab1–40 and Ab1–42 species (Podlisny et al., 1995), and LTP
induction in the hippocampus in vivo is inhibited by their
conditioned medium (7PA2 cell conditioned medium, 7PA2
CM) that contains naturally secreted human Ab oligomers
(Walsh et al., 2002; Townsend et al., 2006a). In normal adult
rats and mice, synaptotoxic Ab oligomers have been found to
potently inhibit hippocampal LTP in vitro (Walsh et al., 2000)
and in vivo (Walsh et al., 2002). Support for the role of low-n
Ab oligomers as a key toxic species has come from Cleary
et al. (2005), who demonstrated that defined molecular
species of the Ab protein cause acute cognitive deficits in the
rat. Specifically, Cleary et al. and others have shown that
soluble oligomeric forms of Ab are both necessary and suffi-
cient to disrupt learned behaviour (Cleary et al., 2005;
Townsend et al., 2006b; Poling et al., 2008).
Preventing Ab aggregation is a therapeutically attractive
neuroprotective approach to preserve synaptic function
because this process is believed to be an exclusively patho-
logical event, and drugs targeting this mechanism are likely
to have a better safety profile than other pharmacothera-
peutic approaches (Amijee and Scopes, 2009). Small mol-
ecule starting points for inhibitors of Ab aggregation are
scarce, and the vast majority of compounds claimed as
inhibitors of Ab aggregation are unsuitable in terms of their
biological profile (Rishton, 2008). RS-0406 (Figure 1) is a
non-peptide small molecule that has been shown to be an
effective inhibitor of Ab toxicity and is also capable of
inhibiting Ab1–42 aggregation (Nakagami et al., 2002). Our
group has used the RS-0406 structure to engineer modifica-
tions that improve potency, specificity and bioavailability to
provide inhibitors of Ab toxicity as improved pharmacologi-
cal tools to better understand the neuroprotection afforded
by such compounds. The novel 5-aryloxypyrimidine,
SEN1269 (Figure 1), shows greater cell penetration and an
improved in vitro ADME profile (Scopes et al., 2008). The
greater cell penetration may additionally allow SEN1269 to
act on intracellular Ab oligomer-producing pathways
(LaFerla et al., 2007). Here, we demonstrate for the first time
that a pharmacologically active, non-peptide, small mol-
ecule was protective against Ab-induced cell death, synap-
totoxicity in vitro and in vivo, and, consequently, prevented
the deficit in cognition induced by 7PA2 CM in a model of
memory in freely moving intact animals.
Methods
Ab1–42 binding, aggregation and cell
viability assays
Surface plasmon resonance was used to measure binding of
SEN1269 to Ab1–42 (see Item S1). Biotinylated Ab1–42 was pre-
pared in 50% dimethyl sulfoxide (DMSO) and pulse injected
into a streptavidin (SA) chip surface until the immobilization
level was established (Biocore T-100 biosensor); 1 mM biotin
was injected into a second flow cell to allow saturation of the
SA chip as control. Binding of SEN1269 in the flow phase
onto immobilized monomeric Ab1–42 was established, and KD
data relative to SEN1269 according to a 1:1 model were deter-
mined. A thioflavin-T assay (LeVine, 1999) was used to quan-
tify Ab fibrillogenesis and to measure SEN1269 inhibition of
Ab1–42 aggregation (see Item S1). Ab1–42 HCl salt was dissolved
in hexafluoroisopropanol, with brief sonification and vortex-
ing. This solution was freeze-dried then dissolved in DMSO.
The ability of SEN1269 (or RS-0406 for comparison) to inhibit
aggregation induced by 10 mM Ab1–42 was assessed by incuba-
tion with Ab1–42 at 37°C for 24 h in PBS. At 24 h, a 50 mL
aliquot was dispensed into a black 96-well plate, and 50 mL
thioflavin T (40 mM in 50 mM glycine buffer) was added to
each well. The plate was shaken, and fluorescence was
recorded using excitation and emission filters of 440  15
and 485  10 nm, respectively. An MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium) assay (Shear-
man et al., 1995) was used to determine the effect of SEN1269
on the deficit in SH-SY5Y cell viability caused by Ab1–42 (see
Item S1). Cell wells were prepared with 3 mL of SEN1269 (or
3 mL RS-0406 for comparison) in DMSO (mixed with 294 mL
Opti-MEM), then 3 mL of Ab1–42 (2 mM) was added and mixed
thoroughly. Fifty microlitres of this solution was aspirated
and dispensed into wells containing 50 mL of media opti-
MEM + SH-SY5Y cells (Ab1–42 final concentration 10 mM), and
the wells were then incubated for 24 h. Fifteen microlitres of
MTT was added to the cell wells, which were then incubated
in 5% CO2 at 37° for 4 h. One hundred microlitres of stop/
solubilization solution was added, and the wells were placed
in a humidified box at room temperature overnight before
reading.
In vitro LTP
Extracellular field excitatory post-synaptic potential (fEPSP)
recordings were made from 400 mm thick transverse hippoc-
ampal slices prepared from male Sprague–Dawley rats
humanely killed by cervical dislocation. After a minimum of
1 h recovery period in aCSF at room temperature, slices were
transferred to an interface chamber, warmed to 30  1°C and
perfused with aCSF. Schaffer collaterals were stimulated
(7–28 V, 0.1 ms pulse width, 0.05 Hz) every 20 s with a con-
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centric bipolar electrode, and fEPSPs were recorded from the
stratum radiatum of the CA1 region (Axoclamp 2A amplifier
and software; pClamp 8.2, Axon, MDS Analytical Technolo-
gies, Sunnyvale, CA, USA) using a glass microelectrode.
Stimulation intensity was set to evoke fEPSPs of approxi-
mately 50% of the maximum amplitude. A minimum 10 min
stable baseline period was recorded before the administration
of test substances in aCSF (30 min application period),
10 min before three periods of high frequency stimulation
(HFS; 1 s of 100 Hz) at 10 min intervals. Ab1–42 experimental
manipulations (see Item S1) consisted of exposure of the
slices to aggregated 1 mM Ab1–42 [33 mM in Tris–HCl + 20 mL
DMSO (stock solution) agitated at 37°C for 24 h using an
orbital shaker], or 20 mL of 5 mM SEN1269 added to the Ab1–42
stock solution and agitated. The control consisted of 20 mL
DMSO in 1 mL Tris–HCl agitated. These agitated solutions
were then diluted to 33 mL in aCSF immediately before they
were applied to the hippocampal slices. 7PA2 CM experimen-
tal manipulations (see Item S1) consisted of slice exposure to
7PA2 CM or CHO CM (control) with DMSO; or 60 mM
SEN1269 added to 7PA2 CM or CHO CM, equilibrated for 1 h
at room temperature and diluted to 20 mL with aCSF prior to
slice application (giving a final SEN1269 concentration of
3 mM). The fEPSPs were recorded for 80 min after the final
HFS stimulation, and the final 10 min of recording (30
sweeps) were selected and averaged for group comparisons
using the unpaired t-test. 7PA2 CM contains a total human
Ab concentration of 3223  1217 pg·mL-1, which is similar to
that found in human CSF (Walsh et al., 2002), and the oligo-
meric Ab species comprises approximately 10–20% of the
total immunoprecipitate of 7PA2 CM (Podlisny et al., 1995).
Using ELISA, it was found that the concentration of total Ab in
the 7PA2 CM used in the LTP and behavioural studies was in
the range of 2–5 nM.
Figure 1
SEN1269 inhibits Ab aggregation, protects cell viability against b1–42-induced insults and binds to b1–42. (A) Surface plasmon resonance response
curves elicited by binding of SEN1269 (0.5, 1, 3, 5, 10, 15, 20 and 30 mM) to monomeric b1–42. (B) Thioflavin-T fluorescence concentration–
response curves of compounds incubated with 10 mM b1–42 for 24 h. (C) Concentration–response curves of compounds incubated with 10 mM
b1–42 for 24 h on SHSY5Y cells using MTT colorimetric assay (cell viability level for 10 mM b1–42 was 10%).
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In vivo LTP
Animals were kept on a 12 h light/dark cycle with food and
water available ad libitum. Extracellular fEPSPs were recorded
from the hippocampi of 36 anaesthetized (urethane i.p. 1 mL
100 g-1 assessed by cardiovascular responses to paw-pinch
and the stability of measured cardiovascular variables with
supplements i.v. of 0.2 mL 100 g-1, 12% solution) adult male
Sprague–Dawley rats. Core body temperature was maintained
at 37°C using a homeothermic blanket, and polyethylene
catheters were inserted into the right femoral artery and vein
for monitoring arterial blood pressure and for anaesthetic
drug administration, respectively. The head was mounted in
a stereotaxic frame before lowering a concentric bipolar
stimulating electrode and carbon fibre recording electrode
vertically into the CA1 area of the hippocampus. Stimulating
electrode coordinates (Paxinos and Watson, 1998): bregma
-3.5 mm, lateral 2.6 mm and 2.0–2.5 mm below the pial
surface, recording electrode coordinates; bregma -4.0 mm,
lateral 3.0 mm and 2.0–2.5 mm below the pial surface. Sub-
sequently, a preloaded 30 gauge stainless steel i.c.v. cannula
was lowered into the lateral ventricle: bregma +0.5 mm,
lateral 1.5 mm and 3.6 mm below the pial surface with a
15–17° rostro-caudal angle. Electrical stimulation (0.1 ms
pulse width, 10–100 V, 0.14 Hz) was used to identify and
optimise fEPSPs, and an input/output curve was created to
determine maximal fEPSP amplitude and the voltage required
to generate fEPSPs of 30–40% of maximum amplitude. Stimu-
lation parameters were maintained at 0.03 Hz, and after a
stable fEPSP had been recorded for 8 min, 7PA2 or CHO CM
with/without SEN1269 (5 mL of 10 or 100 mM SEN1269 added
to 495 mL 7PA2/CHO CM, making final concentrations of
100 nM or 1 mM SEN1269) was administered i.c.v., followed
by further baseline recording (28 min) before HFS of the
Schaffer–collateral pathway. This comprised of three periods
(inter-period interval 30 s) of HFS (10 trains of 10 stimuli;
200 Hz; inter-train interval 50 ms). The fEPSPs were recorded
for 90 min after HFS and the final 10 min of recording (20
sweeps) were selected and averaged for group comparisons
using the unpaired t-test.
Behavioural test
Behavioural data were collected using an alternating-lever
cyclic ratio (ALCR) schedule of food reinforced operant
behaviour, which is recognized as an appropriate and sen-
sitive experimental analysis of behaviour technique (Cleary
et al., 2005). Eighty-four male Sprague–Dawley rats (Harlan,
Oxford, UK), weighing 220–250 g at the beginning of the
experiment, were maintained at 90% of their free-feeding
body weights and housed individually with water available
at libitum in the home cage. The temperature in the vivar-
ium was maintained at 23°C under a 12 h light/12 h dark
cycle (lights on 0800 h). The rats were trained and tested in
two-lever rat test chambers (Med Associates Inc., St. Albans,
NJ, USA) enclosed in sound-proof compartments. Reinforc-
ers were 45 mg sucrose pellets (BioServ, Frenchtown, NJ,
USA), which were delivered into a tray situated midway
between the two operant levers, and ALCR training was
according to the procedure previously reported (Cleary
et al., 2005). Briefly, rats were initially trained to press both
levers, in a two-lever operant chamber, according to an
alternating-lever fixed ratio 1 (FR-1) schedule for reinforce-
ment. During the training, the active lever was extended
into the chamber and illuminated by a light, while the inac-
tive lever was retracted (forced choice). When the rats were
able to obtain 100 reinforcers in 30 min, they were rein-
forced according to a hierarchical series of alternating-lever
FR schedules (FR-2, FR-4, FR-6 and FR-8). They were then
trained under a forced choice arithmetic ALCR schedule,
comprising of an ascending followed by a descending
sequence of the ratio values 3, 6, 9, 12, 15 and 18, over six
cycles, until performance showed no change in trends. They
were then trained under a forced choice ALCR schedule
comprising of an ascending followed by a descending
sequence of the ratio values 2, 6, 12, 20, 30, 42 and 56,
presented over six cycles. When the rats were capable of
completing this forced choice ALCR schedule in 50 min, the
forced choice conditions were removed, both levers were
extended into the chamber and the light cues were extin-
guished. When the rats were capable of completing the ter-
minal ALCR schedule in 50 min, they were anaesthetized
with fentanyl citrate (0.4 mL·kg-1), placed in a sterotaxic
frame and fitted with a permanent indwelling cannula
(23 gauge) aimed at the lateral ventricle of the brain. Half of
the rats received left lateral ventricle cannula implants, and
half received right cannula implants. With the incisor bar
set 3.0 mm below the interaural line, stereotaxic coordinates
(Paxinos and Watson, 1998) were -1.5 mm lateral, 1.0 mm
posterior to bregma and 3.0 mm below the pial surface. The
animals were allowed 10 days for recovery before experi-
mental testing, and cannula placement was verified by the
observation of vigorous drinking (>5.0 mL in 20 min) fol-
lowing i.c.v. injection of 5.0 mL (0.5 mg·mL-1) angiotensin II
(Johnson and Epstein, 1974). Following recovery from
surgery, the animals were randomly assigned to one of six
groups. Group 1 received an i.c.v. injection of 10 mL 7PA2
CM, followed 2 min later by i.c.v. injection of 10 mL DMSO
(the vehicle SEN1269 was dissolved in), to establish the
untreated Ab oligomer behavioural deficit. Group 2 received
i.c.v. injection of 10 mL CHO CM, followed 2 min later by
i.c.v. injection of 10 mL DMSO, to establish response param-
eters in the absence induction of a behavioural deficit or
treatment. Dose-response parameters were then established
in groups 3, 4 and 5, where i.c.v. injection of 10 mL 7PA2
CM was followed 2 min later by i.c.v. injection of (group 3)
10 mL of 100 nM SEN1269, (group 4) 1.0 mM SEN1269 or
(group 5) 10 mM SEN1269. In order to determine any behav-
ioural effects specific to SEN1269, group 6 was injected i.c.v.
with 10 mL CHO CM, followed 2 min later by 10 mL of
10 mM SEN1269. ALCR data were collected 2 h after i.c.v.
injections (Cleary et al., 2005), mean baseline error rates
(lever switching errors and incorrect lever perseverations)
were established and data were analysed as % of overall
baseline performance. To test for motivational or peripheral
motor effects induced by the experimental manipulations,
the slopes of functions were obtained by plotting response
rates against reinforcement rates (motivation) and running
response rates against ratio values (motor retardation) were
compared. Data were analysed by one-way ANOVA followed
by Fisher’s post hoc least significant difference tests.
All studies involving animals are reported in accordance
with the ARRIVE guidelines for reporting experiments involv-
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ing animals (Kilkenny et al., 2010; McGrath et al., 2010). All
studies using animals were conducted under Home Office
License (UK), the UK Animals (Scientific Procedures) Act,
1986 and with Ethics Committee approval from the contrib-
uting institutions.
Results
Ab1–42 binding, aggregation and cell
viability assays
Using surface plasmon resonance (see Item S1), immobilized
Ab1–42 was characterized using A11, OC, 6E10 and 4G8
antibodies: A11 and OC (Ab oligomer and Ab fibril speci-
fic, respectively) showed no binding; whereas 6E10 and
4G8 showed strong binding responses. SEN1269 bound to
monomeric Ab1–42 in a concentration-related manner
(Figure 1A) with a KD of 4.4 mM, which suggests that its
mode of action involves direct interaction with Ab1–42.
SEN1269 also bound to Ab1–42 oligomers (data not shown).
Incubation of SEN1269 with Ab1–42 reduced the fluorescence
exhibited by thioflavin-T (LeVine, 1999) (see Item S1) in a
concentration-related manner (IC50 = 11 mM), indicating
blockade of the Ab aggregation process, and SEN1269 was
more effective in this regard than the parent compound
RS-0406 (Figure 1B). In the MTT assay (Shearman et al.,
1995) (see Item S1), SEN1269 was effective in protecting
neuronal cell lines against an Ab1–42 insult (IC50 = 15 mM)
and was considerably more effective than the parent com-
pound (Figure 1C). As a positive comparator in the
thioflavin-T and MTT assays, the Praecis pentapeptide aggre-
gation inhibitor PPI-1019 (Findeis, 2002) displayed IC50
values of 1.5 and 7 mM, respectively. The cell permeability
of SEN1269 was 20.7 and 17.8 ¥ 10-6 cm·s-1 for apical-
basolateral and basolateral-apical permeability, respectively.
RS-0406 showed corresponding values of 0.9 and 1.8 ¥
10-6 cm·s-1, indicating that biological membranes are highly
permeable to SEN1269.
In vitro LTP
The LTP of fEPSPs in the CA1 region of hippocampal slices
was reduced following application of Ab1–42, from a control
increase of 66.8  10.9% to an increase of 17.5  8.9% after
Ab1–42 application (P < 0.05 vs. control). This effect was com-
pletely reversed by co-incubation of Ab1–42 with SEN1269,
with LTP under these conditions amounting to 77.2  9.6%
(P < 0.05 vs. Ab1–42 alone; Figure 2A–C). SEN1269 (3 mM) was
also effective at reducing the deficit in LTP caused by appli-
cation of cell-derived Ab oligomers (7PA2 CM) to hippocam-
pal slices (Figure 2D–F). Following HFS of the Schaffer
collaterals, the LTP of fEPSPs in control amounted to an
increase of 66.3  6.3% of baseline fEPSP amplitude. In the
presence of 7PA2 CM, the amplitude of fEPSPs following HFS
was lower than that observed prior to HFS, being reduced to
93.7  9.7% (P < 0.05 vs. control) of baseline fEPSPs ampli-
tude (100%). This inhibition of LTP was almost completely
reversed following co-incubation of 7PA2 CM with SEN1269,
the magnitude of LTP being restored to 56.9%  11.9% (P <
0.05 vs. 7PA2 CM alone).
In vivo LTP
In anaesthetized rats, SEN1269 was also effective at prevent-
ing deficits in LTP induced by 7PA2 CM. After i.c.v. adminis-
tration of 7PA2 CM, 30 min before HFS, only a modest LTP of
19.9  8.9% was observed, significantly less than that pro-
duced after administration of control CHO CM; 97.2 12.3%
(P < 0.05 vs. control; Figure 3A–C). This depression of LTP
induced by 7PA2 CM was partly prevented when it was
co-administered with 100 nM SEN1269; the magnitude of
LTP recorded under these conditions amounting to 75.5 
13.3% of baseline fEPSPs (P < 0.05 vs. 7PA2 CM alone;
Figure 3A–C). In a separate set of experiments, i.c.v.
co-administration of 1 mM SEN1269 with 7PA2 CM 30 min
before HFS also significantly prevented the depression of LTP
induced by administration of 7PA2 CM alone. LTP of fEPSPs
observed after 7PA2 CM administration was depressed,
amounting to an increase in fEPSP amplitude of 21.3  7.7%
prevented by co-administration with 1 mM SEN1269, where
LTP amounted to an increase of 98.6  16.0% (P < 0.05 vs.
7PA2 CM alone; Figure 3D–F). In vehicle experiments, after
i.c.v. administration of CHO CM, HFS evoked LTP of 111.2 
14.2%. These data show that SEN1269 protects against the
synaptotoxocity induced by 7PA2 CM.
Behaviour
Following i.c.v. injection of 7PA2 CM in rats trained under
the ALCR schedule, there was a significant overall treatment
effect on lever switching errors 120 min post injection (F5,78
= 3.460, P = 0.0071). The 7PA2 CM injected rats exhibited
significantly more lever switching errors as compared with
the vehicle-injected group (P < 0.05). The 7PA2 CM-injected
groups treated with SEN1269 (100 nM, P = 0.532; 1 mM, P =
0.046; and 10 mM, P < 0.029) demonstrated significantly
fewer lever switching errors than the 7PA2 CM-injected sub-
jects that received vehicle alone (Figure 4A). With respect to
incorrect lever perseverations, there was a significant overall
treatment effect on incorrect lever perseverations 120 min
following 7PA2 CM injections (F5,78 = 8.213, P < 0.0001).
The 7PA2 CM-injected rats exhibited significantly more
incorrect lever perseverations as compared with the vehicle-
injected group (P < 0.0001). The 7PA2 CM-injected groups
treated with SEN1269 (100 nM, P = 0.019; 1 mM, P < 0.009;
and 10 mM, P < 0.0001) demonstrated significantly fewer
incorrect lever perseverations than the 7PA2 CM-injected
subjects that received vehicle alone, and this effect was
dose-dependent (Figure 4B). These findings indicate that
SEN1269, which inhibited the toxic effects of 7PA2 CM on
LTP in vitro and in vivo, was also protective against 7PA2
CM-induced cognitive deficits in vivo. The ALCR schedule
also provides data enabling evaluation of the effects of
experimental manipulations on the ability to track the
changing parameters of the operant schedule, changes in
the motivational state of the animal and peripheral effects
on motor ability. Analysis of the data indicated no signifi-
cant effect of 7PA2 CM or SEN1269 (P-values < 0.05); con-
sequently, the data reported are strongly indicative of
authentic central effects of the experimental manipulations.
These data show that SEN1269 also pharmacologically pro-
tects against synaptotoxocity induced by 7PA2 CM to alle-
viate Ab oligomer-induced memory deficits in vivo.
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Discussion and conclusions
Available therapies only treat the symptoms of AD (Meln-
ikova, 2007; Shah et al., 2008; Wilcock, 2008); however,
disease-modifying pharmacological interventions preventing
the generation of toxic Ab assemblies may have the potential
to slow, or even halt AD progression. RS-0406, a non-peptide
small molecule, has been shown to be an inhibitor of Ab
(Nakagami et al., 2002), to protect primary hippocampal
neurons against Ab1–42-induced cytotoxicity, to rescue syn-
thetic Ab1–42-induced impairment of LTP in hippocampal
slices, to prevent Ab-mediated block of LTP by specifically
inhibiting oligomer formation (Walsh et al., 2005) and to
arrest Ab oligomer-induced behavioural deterioration in the
rat (O’Hare et al., 2010). The current study demonstrates that
a modified version of RS-0406, SEN1269, is pharmacologi-
cally active and is an improved research tool for in vitro and
in vivo use to better understand the relative acute synapto-
toxicity caused by Ab. SEN1269 is a novel, non-peptide small
molecular weight compound that binds to Ab and offers
significant neuroprotection biochemically and in electro-
physiological and behavioural models of memory relevant to
synaptic dysfunction caused by Ab. Thus, surface plasmon
resonance studies illustrated that SEN1269 binds directly to
Ab1–42. The thioflavin-T assay indicated that SEN1269 pro-
duced a concentration-related blockade of Ab1–42 aggregation,
and the MTT assay demonstrated that SEN1269 protected
neuronal cell lines exposed to Ab1–42. These results suggest
that mechanistically SEN1269 acts by binding to Ab to
prevent its assembly and fibrillogenesis, properties of consid-
erable interest given that the key pathogenic event in AD is
believed to be aggregation of the Ab peptide into synapto-
toxic, prefibrillar oligomers (Verdile et al., 2004; Walsh and
Selkoe, 2004a,b).
Figure 2
Inhibition of Ab aggregation and fibrillogenesis by SEN1269 protects against synthetic Ab1–42 and 7PA2 CM-induced deficits in LTP in vitro. (A)
Scatter plot showing the effect of co-administration of SEN1269 (3 mM) + synthetic Ab1–42 (n = 4), Ab1–42 alone (n = 7), vehicle control (n = 4) on
the enhancement of fEPSP amplitude evoked by HFS on hippocampal slices. (B) Histograms showing the level of LTP recorded 80–90 min
post-HFS. ** P < 0.01 compared to control, †† P < 0.01 compared to Ab1–42, † P < 0.05 compared to Ab1–42. (C) Typical fEPSPs before and 80 min
after HFS for the three treatment groups. Traces shown are the average of 10 sweeps. (D) Scatter plot showing the effect of co-administration of
SEN1269 (3 mM) + 7PA2 CM (n = 4), 7PA2 CM alone (n = 4) CHO CM alone (n = 4) on the enhancement of fEPSP amplitude evoked by HFS on
hippocampal slices. (E) Histograms showing the level of LTP recorded 80 min post HFS. ** P < 0.01 compared to CHO CM, †† P < 0.01 compared
to 7PA2 CM, † P < 0.05 compared to 7PA2 CM. (F) Typical fEPSPs before and 80 min after HFS for the three treatment groups. Traces shown are
the average of 10 sweeps.
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Electrophysiological studies confirmed that in vitro and
in vivo LTP of synaptic transmission, considered to underlie
synaptic plasticity associated with learning and memory, was
compromised by synthetic Ab1–42 or cell-derived Ab oligomers
(7PA2 CM); and that these effects were reversed by incubation
of SEN1269 with Ab1–42 or 7PA2 CM. Thus, SEN1269 protects
against Ab-induced synaptotoxicity. Low-n oligomers are
present in 7PA2 CM at low- to sub-nanomolar concentra-
tions, similar to those of Ab in human CSF (Walsh et al.,
2002), and it has been established that these cell-derived Ab
oligomers are composed of N- and C-terminally heterogene-
ous human Ab peptides, including the Ab1–40 and Ab1–42
species that occur in the human brain and extracellular fluids
(Podlisny et al., 1995; 1998; Walsh et al., 2002; 2005). Further-
more, in freely moving intact animals trained to respond
under a complex schedule of food reinforced behaviour,
SEN1269 significantly reduced numbers of lever switching
errors and incorrect lever perseverations induced by i.c.v.
7PA2 CM injections. There were no significant differences in
reinforcement rates or running response rates between the
7PA2 CM-injected groups treated with SEN1269 and the 7PA2
CM-injected group that received vehicle, demonstrating that
SEN1269 neither increased nor decreased the motivational
state or peripheral motor output of the animals, and indicat-
ing that the behavioural effect of SEN1269 was central and
rescued cognitive processes.
A number of studies have established that Ab1–42 is the
more neurotoxic form of Ab (McGowan et al., 2005), Ab1–40
and Ab1–42 possess different biochemical properties, and Ab1–42
is considered to be the major aetiological agent in the patho-
genesis of AD due to its more aggressive aggregation or oli-
gomerization properties (Burdick et al., 1992; Jarrett et al.,
1993). Compelling evidence indicates that the toxic amyloid
species underlying the cognitive deficit in AD are soluble
Figure 3
Inhibition of Ab aggregation and fibrillogenesis by SEN1269 protects against 7PA2 CM-induced deficits in LTP in vivo. (A) Scatter plot showing the
effect of co-administration of SEN1269 (100 nM) + 7PA2 CM (n = 6), 7PA2 CM alone (n = 4) and CHO CM (n = 4) on the enhancement of fEPSP
amplitude evoked by HFS in the CA1 region of the hippocampus in an anaesthetized rat. (B) Histograms showing the level of LTP recorded 90 min
post-HFS. ** P < 0.01 compared to CHO CM, † P < 0.05 compared to 7PA2 CM. (C) Typical fEPSPs before and 80 min after HFS for the three
treatment groups. Traces shown are the average of 10 sweeps. (D) Scatter plot showing the effect of co-administration of SEN1269 (1 mM) + 7PA2
CM (n = 6), 7PA2 CM alone (n = 10) and CHO CM (n = 5) on the enhancement of fEPSP amplitude evoked by HFS in the CA1 region of the
hippocampus in an anaesthetized rat. (E) Histograms showing the level of LTP recorded 90 min post-HFS. ** P < 0.01 compared to CHO CM,
†† P < 0.01 compared to 7PA2 CM. (F) Typical fEPSPs before and 80 min after HFS for the three treatment groups. Traces shown are the average
of 10 sweeps.
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low-n oligomers of the Ab peptide, which subsequently form
insoluble amyloid fibrils via association of the peptide
b-strands (Walsh and Selkoe, 2007; Klyubin et al., 2008), and
Ab dimers have been identified as the smallest synaptotoxic
species in Alzheimer’s brains (Shankar et al., 2008). Oligo-
meric Ab is able to permeate biological membranes (Glabe,
2006) and the current study used conditioned medium from
7PA2 cells, which contains low-n Ab oligomers, to induce
electrophysiological and behavioural deficits. Our pharmaco-
logical observations lend support to the biological hypothesis
that inhibiting the process of Ab peptide aggregation cen-
trally may be a viable neuroprotective strategy to potentially
treat AD. Moreover, SEN1269 is the first non-peptide small
molecule (molecular weight 321) that binds to Ab monomer
and oligomers, inhibits Ab fibrillogenesis, maintains cell
viability against a toxic insult of Ab1–42, prevents the deficit in
LTP caused by synthetic Ab1–42 or cell-derived oligomers of Ab
and is effective in protecting against the deficit in cognition
induced by cell-derived oligomers of Ab in a behavioural
model of memory relevant to synaptic dysfunction caused by
Ab. As synaptic loss underlies the neuropathology of AD,
these new acute data on SEN1269 provide support for the
design of further molecules in this structural class, which are
orally bioavailable, CNS penetrating and that have therapeu-
tically useful half-lives suitable for testing in chronic animal
models that are thought to be relevant to the neuropathology
of AD. In the future, development of an orally bioavailable
analogue of SEN1269 would be of interest as a potential
disease-modifying treatment of AD.
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